Effects of valproic acid on the cell cycle and apoptosis through acetylation of histone and tubulin in a scirrhous gastric cancer cell line

Journal of Experimental and Clinical Cancer Research

Volumn 29, Issue 1, 2010, Pages

  Yagi, Yasumichi ^a   Fushida, Sachio ^a   Harada, Shinichi ^a   Kinoshita, Jun ^a   Makino, Isamu ^a   Oyama, Katsunobu ^a   Tajima, Hidehiro ^a   Fujita, Hideto ^a   Takamura, Hiroyuki ^a   Ninomiya, Itasu ^a   Fujimura, Takashi ^a   Ohta, Tetsuo ^a   Yashiro, Masakazu ^b   Hirakawa, Kosei ^b  

^a KANAZAWA UNIVERSITY   (Japan)

^b OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TUBULIN; CASPASE 3; CASPASE 9; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE H3; PACLITAXEL; PROTEIN BCL 2; PROTEIN P27; SURVIVIN; VALPROIC ACID; ANTINEOPLASTIC AGENT; HDAC1 PROTEIN, HUMAN; HDAC2 PROTEIN, HUMAN; HISTONE; TUBULIN;

ACETYLATION; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER SIZE; CELL CYCLE; CELL CYCLE REGULATION; CELL VIABILITY; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG ACTIVITY; DRUG EFFECT; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCIRRHOUS GASTRIC CANCER; STOMACH CANCER; TUMOR XENOGRAFT; UPREGULATION; WESTERN BLOTTING; ADENOCARCINOMA; ANIMAL; CANCER INVASION; DRUG SCREENING; IMMUNOHISTOCHEMISTRY; METABOLISM; NUDE MOUSE; PATHOLOGY; STOMACH TUMOR; TUMOR CELL LINE;

ACETYLATION; ADENOCARCINOMA, SCIRRHOUS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL LINE, TUMOR; FEMALE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONES; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; STOMACH NEOPLASMS; TUBULIN; VALPROIC ACID; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 78249234725     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-29-149     Document Type: Article

References (61)

1. Concepts in the prevention of adenocarcinoma of the distal esophagus and proximal stomach. RF Souza SJ Spechler, CA cancer J Clin 2005 55 334 51
2. Recent results of therapy for scirrhous gastric cancer. M Ikeguchi T Miyake T Matsunaga,, et al. Surg Today 2009 39 290 4
3. Peritoneal carcinomatosis and lymph node metastasis are prognostic indicators in patients with Borrmann type IV gastric carcinoma. CY Chen CW Wu SS Lo MC Hsieh WY Lui KH Shen, Hepatogastroenterology 2002 49 874 7
4. Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis. H Ishigami J Kitayama S Kaisaki,, et al. Ann Oncol 2010 21 67 70
5. Dual anti-cancer effects of weekly intraperitoneal docetaxel in treatment of advanced gastric cancer patients with peritoneal carcinomatosis: a feasibility and pharmacokinetic study. S Fushida J Kinoshita Y Yagi,, et al. Oncol Rep 2008 19 1305 10
6. Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. MA Shah RK Ramanathan DH Ilson,, et al. J Clin Oncol 2006 24 5201 6
7. Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). C Pinto F Di Fabio S Siena,, et al. Ann Oncol 2007 18 510 7
8. Resistance of pancreatic cancer to gemcitabine treatment is dependent on mitochondria-mediated apoptosis. B Schniewind M Christgen R Kurdow,, et al. Int J Cancer 2004 109 182 8
9. Effects of histone acetylation and DNA methylation on p21 (WAF1) regulation. JY Fang YY Lu, World J Gastroenterol 2002 8 400 5
10. Translating the histone code. T Jenuwein CD Alli's, Science 2001 293 1074 80
11. Control of chromatin remodeling. JR Davie M Moniwa, Crit Rev Eukaryotic Gene Expression 2000 10 303 25
12. Deacetylase enzymes: biological functions and the use of small-molecule inhibitors. CM Grozinger SL Schreiber, Chem Biol 2002 9 3 16
13. The human histone deacetylase family. SG Gray TJ Ekström, Exp Cell Res 2001 262 75 83
14. Histone deacetylase inhibitors. C Monneret, Eur J Med Chem 2005 40 1 13
15. Histone deacetylase inhibitors:gathering pace. N Carey NB La Thangue, Curr Opin Pharmacol 2006 6 369 75
16. Effect of Trichostatin A on cell growth and expression of cell cycle-and apoptosis-related molecules in human gastric and oral carcinoma cell lines. T Suzuki H Yokozaki H Kuniyasu,, et al. Int J Cancer 2000 88 992 7
17. Histone deacetylase inhibitor, trichostatin A, increases the chemosensitivity of anticancer drugs in gastric cancer cell lines. X Zhang M Yashiro J Ren,, et al. Oncol Rep 2006 16 563 8
18. Valproic acid inhibits the growth of cervical cancer both in vitro and in vivo. S Sami N Höti HM Xu Z Shen X Huang, J Biochem 2008 144 357 62
19. The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2. OH Kramer P Zhu HP Ostendorff,, et al. EMBO J 2003 22 3411 20
20. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. M Göttlicher S Minucci P Zhu,, et al. EMBO J 2001 20 6969 78
21. Valproate inhibition of histone deacetylase 2 affects differentiation and decreases proliferation of endometrial stromal sarcoma cells. A Hrzenjak F Moinfar ML Kremser,, et al. Mol Cancer Ther 2006 5 2203 10
22. p21Waf1/Cip1 is a common target induced by short-chain fatty acid HDAC inhibitors (valproic acid, tributyrin and sodium butyrate) in neuroblastoma cells. P Rocchi R Tonelli C Camerin,, et al. Oncol Rep 2005 13 1139 44
23. Human endometrial and ovarian cancer cells: histone deacetylase inhibitors exhibit antiproliferative activity, potently induce cell cycle arrest, and stimulate apoptosis. N Takai H Narahara, Curr Med Chem 2007 14 2548 53
24. Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. X Yu ZS Guo MG Marcu,, et al. J Natl Cancer Inst 2002 94 504 13
25. Histone deacetylase inhibitors all induce p21 but differentially cause tubulin acetylation, mitotic arrest, and cytotoxicity. MV Blagosklonny R Robey DL Sackett,, et al. Mol Cancer Ther 2002 1 37 41
26. Valproic acid enhances tubulin acetylation and apoptotic activity of paclitaxel on anaplastic thyroid cancer cell lines. MG Catalano R Poli M Pugliese N Fortunati G Boccuzzi, Endocr Relat Cancer 2007 14 839 45
27. The taxoids: paclitaxel and docetaxel. K Gelmon, Lancet 344 1267 72
28. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. M Markman BN Bundy DS Alberts,, et al. J Clin Oncol 2001 19 1001 7
29. Histone deacetylase is a target of valproic acid-mediated cellular differentiation. N Gurvich OM Tsygankova JL Meinkoth PS Klein, Cancer Res 2004 64 1079 86
30. Cyclins and cell cycle checkpoints. DG Johnson CL Walker, Annu Rev Pharmacol Toxicol 1999 39 295 312
31. Role of p53 status in chemosensitivity determination of cancer cells against histone deacetylase inhibitor sodium butyrate. J Joseph N Wajapeyee K Somasundaram, Int J Cancer 2005 115 11 8
32. The histone deacetylase inhibitor FR901228 (desipeptide) restores expression and function of pseudo-null p53. M Kitazono S Bates P Fok T Fojo MV Blagosklonny, Cancer Biol Ther 2002 1 665 8
33. Fibrosis in the peritoneum induced by scirrhous gastric cancer cells may act as 'soil' for peritoneal dissemination. M Yashiro YS Chung S Nishimura T Inoue M Sowa, Cancer 1996 77 1668 75
34. Inhibitory effect of a TGFbeta receptor type-I inhibitor, Ki26894, on invasiveness of scirrhous gastric cancer cells. O Shinto M Yashiro H Kawajiri,, et al. Br J Cancer 2010 102 844 51
35. Over expression of transforming growth factor-beta1 in scirrhous carcinoma of the stomach correlates with decreased survival. S Kinugasa S Abe M Tachibana,, et al. Oncology 1998 55 582 7
36. Transforming growth factor-beta and hepatocyte growth factor produced by gastric fibroblasts stimulate the invasiveness of scirrhous gastric cancer cells. T Inoue YS Chung M Yashiro,, et al. Jpn J Cancer Res 1997 88 152 9
37. TGF-beta1 secreted by gastric fibroblasts up-regulates CD44 H expression and stimulates the peritoneal metastatic ability of scirrhous gastric cancer cells. T Koyama M Yashiro T Inoue,, et al. Int J Oncol 2000 16 355 62
38. The pathophysiology of epithelial-mesenchymal transition induced by transforming growth factor-beta in normal and malignant mammary epithelial cells. MA Taylor JG Parvani WP Schiemann, J Mammary Gland Biol Neoplasia 2010 15 169 90
39. Transforming growth factor-beta signaling in epithelial-mesenchymal transition and progression of cancer. K Miyazono, Proc Jpn Acad Ser B Phys Biol Sci 2009 85 314 23
40. Epithelial-mesenchymal transition in cancer progression. M Gos J Mioszewska M Przybyszewska, Postepy Biochem 2009 55 121 8
41. Histone deacetylase 4 is required for TGFbeta1-induced myofibroblastic differentiation. W Glenisson V Castronovo D Waltregny, Biochim Biophys Acta 2007 1773 1572 82
42. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. N Khan M Jeffers S Kumar,, et al. Biochem J 2008 409 581 9
43. HDAC-6 interacts with and deacetylates tubulin and microtubules in vivo. Y Zhang N Li C Caron,, et al. EMBO J 2003 22 1168 79
44. Histone deacetylase inhibitors all induce p21 but differentially cause tubulin acetylation, mitotic arrest, and cytotoxicity. MV Blagosklonny R Robey DL Sackett,, et al. Mol Cancer Ther 2002 1 937 41
45. HDAC6 is a microtubule-associated deacetylase. C Hubbert A Guardiola R Shao,, et al. Nature 2002 417 455 8
46. Histone deacetylase inhibitors and paclitaxel cause synergistic effects on apoptosis and microtubule stabilization in papillary serous endometrial cancer cells. SC Dowdy S Jiang XC Zhou,, et al. Mol Cancer Ther 2006 5 2767 76
47. Low-dose paclitaxel ameliorates renal fibrosis in rat UUO model by inhibition of TGF-beta/Smad activity. D Zhang L Sun W Xian,, et al. Lab Invest 2010 90 436 47
48. Paclitaxel interrupts TGF-beta1 signaling between gallbladder epithelial cells and myofibroblasts. HS Choi CE Savard JW Choi R Kuver SP Lee, J Surg Res 2007 141 183 91
49. Paclitaxel modulates TGFbeta signaling in scleroderma skin grafts in immunodeficient mice. X Liu S Zhu T Wang,, et al. PLoS Med 2005 2 354
50. Abrogation of TGF-beta1-induced fibroblast-myofibroblast differentiation by histone deacetylase inhibition. W Guo B Shan RC Klingsberg X Qin JA Lasky, Am J Physiol Lung Cell Mol Physiol 2009 297 864 70
51. Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial. A Atmaca SE Al-Batran A Maurer,, et al. Br J Cancer 2007 97 177 82
52. A phase I-II study of the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patients with advanced melanoma. A Rocca S Minucci G Tosti,, et al. Br J Cancer 2009 100 28 36
53. A phase II study to establish the efficacy and toxicity of sodium valproate in patients with cancer-related neuropathic pain. JR Hardy EA Rees B Gwilliam J Ling K Broadley R A'Hern, J Pain Symptom Manage 2001 21 204 9
54. Targeting cancer and neuropathy with histone deacetylase inhibitors: two birds with one stone? V Rodriguez-Menendez L Tremolizzo G Cavaletti, Curr Cancer Drug Targets 2008 8 266 74
55. Phase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancers. F Braiteh AO Soriano G Garcia-Manero,, et al. Clin Cancer Res 2008 14 6296 301
56. Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I/II trial of valproic acid and epirubicin/FEC. P Munster D Marchion E Bicaku,, et al. Clin Cancer Res 2009 15 2488 96
57. Expression profile of class I histone deacetylases in human cancer tissues. M Nakagawa Y Oda T Eguchi,, et al. Oncol Rep 2007 18 769 74
58. Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis. W Weichert A Röske V Gekeler,, et al. Lancet Oncol 2008 9 139 48
59. Expression profile of histone deacetylase 1 in gastric cancer tissues. JH Choi HJ Kwon BI Yoon,, et al. Jpn J Cancer Res 2001 92 1300 4
60. Increased expression of histone deacetylase 2 is found in human gastric cancer. J Song JH Noh JH Lee,, et al. APMIS 2005 113 264 8
61. Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis. W Weichert A Röske V Gekeler,, et al. Lancet Oncol 2008 9 139 48